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Background. The decreasing image quality in heavier patients can be compensated by
administration of a patient-specific dose in myocardial perfusion imaging (MPI) using a cad-
mium zinc telluride-based SPECT camera. Our aim was to determine if the same can be
achieved when using a conventional SPECT camera.
Methods. 148 patients underwent SPECT stress MPI using a fixed Tc-99m tetrofosmin
tracer dose. Measured photon counts were normalized to administered tracer dose and scan
time and were correlated with body weight, body mass index, and mass per length to find the
best predicting parameter. From these data, a protocol to provide constant image quality was
derived, and subsequently validated in 125 new patients.
Results. Body weight was found to be the best predicting parameter for image quality and
was used to derive a new dose formula; Aadmin (MBq) 5 223body weight (kg)0.65/Tscan (min).
The measured photon counts decreased in heavier patients when using a fixed dose (P < .01) but
this was no longer observed after applying a body-weight-dependent protocol (P 5 .20).
Conclusions. Application of a patient-specific protocol resulted in an image quality less
depending on patient’s weight. The results are most likely independent of the type of SPECT
camera used, and, hence, adoption of patient-specific dose and scan time protocols is recom-
mended. (J Nucl Cardiol 2015)
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Abbreviations
MPI Myocardial perfusion imaging
SPECT Single-photon emission computed
tomography
CZT Cadmium zinc telluride
BMI Body mass index
INTRODUCTION
Myocardial perfusion imaging (MPI) using single-
photon emission computed tomography (SPECT) is one
of the most validated non-invasive methods to test for
ischemia in patients suspected of stable coronary artery
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disease.1 Remarkably, the dosages to administer vary
widely between institutions, and in most European
countries, fixed tracer doses are recommended.2 Yet, a
decreasing image quality is observed in heavier patients
in clinical practice. The European (EANM/ESC) guide-
lines still recommend a fixed tracer dose,2 whereas the
American (ASNC) guidelines propose to adjust the dose
upward for patients heavier than 70 kg by 11.5 MBq/kg
for Tc-99m.3 However, no references for this adjustment
are provided, and possible differentiation to account for
a different scanner set-up or sensitivities is not
mentioned.
Several studies have demonstrated a decrease in
measured photon counts for increasing body weights.4-7
They propose different correction formulas to compen-
sate for this decrease. Those methods were mainly
focused on correcting for heavier patients, and only one
correction formula was validated in clinical practice.8
This validation was only performed in patients weighing
more than 100 kg, ignoring the possible benefit of a
lower dose for leaner patients. Moreover, the influence
on image quality by reader interpretation was not
assessed.8
We recently developed a method to derive a body-
weight-dependent tracer dose or scan time protocol.
Application led to a constant image quality in MPI using
a gamma camera equipped with cadmium zinc telluride
(CZT) detectors.9 This validated protocol seems not
directly applicable on conventional gamma cameras,
equipped with sodium iodide crystals, due to their lower
detector sensitivity, image contrast, and different detec-
tor configuration.10-12 Hence, the aim of this study was
to test if introducing a patient-specific dose and scan
time protocol for MPI SPECT using a conventional
camera results in an image quality independent of
patients’ physical characteristics.
MATERIALS AND METHODS
In this study, we used a comparable methodology as
previously described by van Dijk et al.9 All patients were
scanned according to the standard clinical protocol valid at the
time of acquisition. Based on the outcomes of the tracer dose
and scan time deriving part of this study, the clinical protocol
was changed in the hospital. For this reason, approval by the
medical ethics committee was not required. All patients
provided written informed consent for the use of their data
for research purposes.
Study Population
We retrospectively included a total of 273 consecutive
patients who underwent clinically indicated SPECT stress MPI
on a conventional dual-detector gamma camera (Ventri, GE
Healthcare). All patients underwent a stress-first 1-day Tc-99m
tetrofosmin SPECT protocol. The first 105 patients were
included in the dose and scan time deriving part of this study
(further referred to as group A). To obtain a patient population
with a sufficient amount of patients in the full range of body
weights that are encountered in clinical practice, another 43
patients were specifically added such that at least 10 patients
fell into one of the following body weight categories:\60,
60-70, 71-80, 81-90, 91-100, 101-110, 111-120, 121-130, and
[130 kg. Moreover, additional 99 patients were consecutively
included for the validation part of this study, and another 26
patients were added to obtain a similar amount of patients in
each body weight category as in group A (further referred to as
group B).
Patient Preparation and Image Acquisition
Patients were requested not to use any nicotine- or
caffeine-containing beverages for 24 hours and to discontinue
persantin for 48 hours prior to scanning. Pharmacological
stress was induced by intravenous adenosine (140 lg/kg/min
for 6 minutes) or regadenoson (5 mL with 400 lg for 15 sec-
onds followed by a saline flush). Only pharmacologic stress
was used due to logistic reasons, in particular the high patient
throughput in our center.13 A fixed tracer dose of 370 MBq Tc-
99m tetrofosmin (500 MBq for patients with a body weight of
more than 100 kg) was administered intravenously at peak
stress in group A.
Patients were requested to consume at least half a
chocolate bar and drink three cups of water post-injection to
reduce sub-diaphragmatic activity uptake and improve image
quality of the inferior wall. Stress imaging was performed 45-
60 minutes post-injection. All patients were scanned in supine
position, with their arms placed above their heads using a fixed
scan time of 10 minutes. Images were acquired using a double
detector, low-energy high-resolution collimator, with an ellip-
tical orbit with step-and-shoot acquisition at 6 intervals over a
180 arc (45 anterior oblique to 45 left posterior oblique)
with 15 views (40 seconds per view), and a 64 9 64 matrix
using a 20% symmetrical energy window centered at 140 keV.
Subsequently, the emission images were reconstructed by
applying an iterative dedicated reconstruction algorithm with
maximum-likelihood expectation maximization (Myovation,
GE Healthcare). Each image was automatically normalized to
the maximum peak activity, and the segmental uptake values
were presented as the percentage of the maximum myocardial
regional uptake. The images were displayed in the traditional
short, vertical long, and horizontal long axes and reviewed
using a color scale.
Deriving a Patient-Specific Tracer Dose and
Scan Time Protocol
First, the total number of measured photon counts in the
myocardial region was determined in the raw-emission data for
each scan. This was done by summing the 30 (2 detec-
tors 9 15 views) raw-emission images into one image and
consecutively manually drawing an elliptical region of interest
covering all myocardium positions, as shown in Figure 1.
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Using elliptical regions allowed us to exclude surrounding
activity and to include only the counts originating from the
myocardial region.
Next, the measured photon counts were normalized to the
product of the tracer dose corrected for radioactive decay and
scan time, Tscan (min). To find the patient-specific parameter
(P) best explaining the decrease in image quality for heavier
patients, the normalized photon counts, Cnorm, were fitted to
three patients’ physical characteristics: body weight, mass per
length, and body mass index (BMI) using a power-law
function:
Cfit ¼ a  Pb: ð1Þ
Here, a and b are fit parameters. Parameter selection was based
on practicality in use and power to correct for the varying
image quality in MPI as previously demonstrated.9
When a decrease in the normalized photon counts can be
explained by a patient-specific parameter, this allows making a
Figure 1. An example of (A) 15 of the 30 raw-emission images covering the myocardial region
and (B) the image showing the summation of all 30 raw-emission images including the manually
drawn elliptical region of interest covering all myocardium positions to determine the measured
photon counts.
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correction using the tracer dose and/or scan time. Subse-
quently, this can be used to derive a protocol resulting in a
constant number of counts (C), and accordingly a constant
image quality, ideally independent of patients’ physical char-
acteristics.9 For this study, C was set equal to the average
number of photon counts measured in all scans. The following
formula describes the relation between C and the recom-
mended patient-specific scan time and/or tracer dose to be
administered, Aadmin:
C ¼ Cfit  Aadmin  Tscan
K
: ð2Þ
Here, K is the correction factor for radioactive decay between
administration of tracer dose and SPECT acquisition (1.12 for
60 minutes). A linear count rate response was assumed
because the maximal count rate encountered in this study
(6 kcounts/second) was much lower than the count rates
associated with the occurrence of dead time effects in con-
ventional cameras ([200 kcounts/second).14
When combining Eqs. 1 and 2, this results into
Aadmin ¼ C  P
b  K
a  Tscan : ð3Þ
Equation 3 shows that Aadmin and Tscan are interchange-
able, as suggested by Oddstig et al15 i.e., instead of introducing
a patient-specific dose, a patient-specific scan time may be
adopted. In addition, the dose to administer can be reduced,
while increasing the scan time to obtain the same image quality
up to certain limits due to possible patient motion.
Validating the Derived Tracer Dose and
Scan Time Protocol
The derived tracer dose and scan time formula, according
to Eq. 3, was implemented in our routine clinical protocol.
The image quality for all 247 reconstructed myocardium
images in both group A and B was scored by three independent
experienced nuclear medicine physicians with overread in case
of discordance by a fourth expert. A visual 4-point grading
scale (1-poor, 2-fair, 3-good, and 4-excellent) was employed.
The following parameters were considered: myocardial count
density and uniformity in well-perfused areas, signal to
background noise, and shape of the left ventricle. All readers
were blinded for patient characteristics, and the images were
presented in random order.
The image quality was compared between groups A and
B. The correlation between the best explaining parameter and
both the image quality and measured photon counts was
assessed to determine if they were independent when applying
a patient-specific protocol.
Statistics
All patient-specific parameters and characteristics were
determined as mean ± standard deviation (sd) and compared
using the chi-square and unpaired t-tests using Stata software
(StataSE 12.0). To test if the slope of Cfit differed significantly
from zero for each patient-specific parameter, implying a
significant correlation with Cnorm, t-tests were performed.
Coefficients of determination (R2) were determined for all fits,
and the fit errors were calculated for each data point using
(Cfit - Cnorm)/Cfit100%. To determine if the fit results differed
between the three selected parameters, the fit error distribu-
tions were compared using the F-test. Next, the patient-specific
parameter best explaining the normalized photon counts was
selected using the results of R2 and the F-tests. The correlation
between the best explaining parameter and both the measured
photon counts and image quality was calculated in both groups
using the Pearson correlation coefficient and the Spearman’s
rank correlation coefficient, respectively. In addition, the
correlation between measured photon counts and image quality
was calculated using the Spearman’s rank correlation coeffi-
cient. Furthermore, the influence of interpreted scan outcomes
on the image quality was assessed using the chi-square test.
The body weight for the patient scans interpreted as normal or
abnormal was compared for both groups using a t-test.
The level of statistical significance was set to 0.05 for all
statistical analyses.
RESULTS
The baseline characteristics of all included patients
are summarized in Table 1.
Deriving a Patient-Specific Tracer Dose and
Scan Time Protocol
The mean number of measured photon counts in
the myocardial region in group A was 812 9 103 ±
197 9 103. This was 236 ± 62 countsMBq-1min-1 for
the normalized photon counts.
The slope of all three fits, describing the relation
between the normalized photon counts and the three
patient-specific parameters, was found to be statistically
different from zero (P\ .001), as illustrated in Figure 2.
As hypothesized, the measured photon counts normal-
ized to dose and scan time decreased for all patient-
specific parameters, explaining the lower image quality
encountered in heavier patients in clinical practice. The
calculated fit parameters a and b and the coefficient of
determination are shown in Table 2.
Body weight was chosen as the patient-specific
parameter best explaining the normalized photon counts
based on its practicality in use, a comparable standard
deviation of the error distributions (P[ .7) and R2
value, and was further used in this study.
Using Eq. 3, a body-weight-dependent patient-
specific dose and scan time protocol was derived and
consecutively validated. The protocol can be described
by Aadmin (MBq) = 223body weight (kg)0.65/Tscan (min)
or Aadmin (mCi) = 6.0body weight (kg)0.65/Tscan (min),
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and is illustrated in Figure 3 and shown in Table 3. This
formula is based on patients with body weights ranging
between 60 and 130 kg, and hence, the tracer dose
ranged from 319 to 564 MBq.
Validating the Derived Tracer Dose and
Scan Time Protocol
The mean number of measured photon counts in the
myocardial region in group B was 947 9 103 ±
188 9 103. This was 276 ± 71 countsMBq-1min-1
for the normalized photon counts.
Within the set of scored images, 3% and 0% were
scored as poor, 31% and 33% as fair, 63% and 59% as
good, and 3% and 8% as excellent in group A and B,
respectively. The interpreted image quality decreased
for heavier patients in both group A (P\ .001) and
group B (P = .003), as illustrated in Figure 4. However,
different correlations between the measured photon
counts and body weight were observed between both
groups, as illustrated in Figure 5. A significant correla-
tion between counts and body weight was observed in
group A (P\ .001), whereas this correlation was absent
in group B (P = .29). Moreover, a significant
Table 1. Baseline characteristics, interpreted scan outcomes, and administered tracer dose of all 273
patients who underwent clinically indicated MPI SPECT
Characteristic
Group A
(n 5 148)
Group B
(n 5 125)
p value (chi-square/
t-test)
Age (years) 67.5 ± 10.8 68.5 ± 9.8 0.43
Male gender (%) 55.4 66.4 0.06
Body weight (kg) 85.1 ± 22.2 87.3 ± 22.1 0.45
Height (cm) 172 ± 10.2 174 ± 9.5 0.08
BMI (kg/m2) 28.6 ± 6.3 28.5 ± 5.8 0.91
Current smoking (%) 15.2 10.5 0.31
Hypertension (%) 62.3 57.0 0.52
Diabetes (%) 26.1 30.7 0.43
Dyslipidemia (%) 63.7 54.5 0.17
Family history (%) 66.4 56.9 0.09
Normal MPI scan (%) 34.3 38.2 0.60
Ischemic defect (%) 32.4 35.5 0.61
Non reversible defect (%) 44.5 40.9 0.59
Tracer dose at acquisition (MBq) 343 ± 70 352 ± 57 0.23
Data are presented as mean ± standard deviation or percentages
Figure 2. Measured photon counts normalized to tracer dose and scan time as a function of (A) body weight, (B) BMI, and (C) mass
per length. The solid lines represent the power-law fits and the coefficients of determination are also shown for each fit.
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correlation was found between measured photon counts
and image quality in both group A and B (P = .01 and
.03, respectively).
Patients with scans interpreted as normal had a
significant higher image quality in both groups
(P\ .003). In addition, patients without a normal scan
were significantly heavier in group B (P = .02),
whereas this was not the case in group A (P = .18).
DISCUSSION
In the present study, we derived and subsequently
validated a body-weight depending tracer dose and scan
time protocol to obtain a more constant image quality
independent of patients’ physical characteristics in MPI
using SPECT. Although a significant decreasing image
quality was observed for heavier patients in both group
A and B, the measured photon counts became indepen-
dent of body weight after applying the new protocol.
Hence, we can assume that a patient-specific protocol in
MPI using a conventional SPECT camera results in a
more consistent image quality less dependent of
patient’s physical characteristics.
Similar nonlinear relations between normalized
photon counts and body weight as found in this study
were observed previously.4-7,9 Yet, the derived formulas
to correct for the decreasing photon counts in heavier
patients vary. After normalizing these formulas to an
average patient of 80 kg, the correction factors to adjust
the tracer dose for a 130 kg patient vary between 1.4 and
2.3, as illustrated in Figure 6. These differences are most
likely due to the variation in methodologies used to
estimate the photon counts originating from the myo-
cardium. The studies which measured the photon counts
in the raw-emission images, to eliminate possible
influences of reconstruction algorithms, all propose
correction factors varying between 1.4 and 1.6 for a
130 kg patient.5,9 However, higher correction factors are
proposed by the studies which estimated the counts in a
region of interest in the reconstructed images, resulting
in correction factors varying between 1.7 and 2.3.4-7 Yet,
a part of the variation in correction formulas might also
be due to the exclusion of patients, for example, patients
with perfusion defects,5 three vessel disease,6 or who
Table 2. Fit parameters describing the relation between the normalized photon counts and each
patient-specific parameter, including the coefficients of determination (R2) and result of the error
distribution comparison
Parameter a (95% CI) b (95% CI) R2 F-test (P value)
Body weight 4063 (2174:7593) -0.65 (-0.80:-0.51) 0.36 Reference
BMI 3812 (2160:6727) -0.85 (-1.02:-0.68) 0.40 0.79
Mass per length 4666 (2547:8551) -0.78 (-0.94:-0.62) 0.39 0.73
Figure 3. Line graph demonstrating the previously applied
fixed Tc-99m tracer dose and scan time product (Afixed) and the
derived body-weight-dependent patient-specific protocol (see
Eq. 3) as applied in group B (Aadmin), including the 95%
confidence interval. The right y-axis shows the product of the
effective patient dose and scan time.
Figure 4. Boxplot showing the relation between body weight
and scored image quality for both patient groups. A significant
relation was found for group A (fixed tracer dose, P = .01) and
group B (body-weight depending tracer dose, P = .03).
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underwent rest imaging.7 Only three studies, including
the present study, are known to have validated their
correction formula in clinical practice.8,9 Notghi et al
and van Dijk et al also demonstrated to obtain a constant
image quality independent of patients’ physical charac-
teristics. Yet, we are the first to demonstrate that a
patient-specific formula is also applicable in patients
weighing less than 100 kg when using a conventional
SPECT camera.8 Moreover, it seems that the higher
correction factors as derived and proposed in the non-
validated studies, as illustrated in Figure 6, are not
necessary.
There is a large variation in the correction formulas
as proposed by our study and the other two validated
studies. These differences might be explained by the use
of different fits to describe the relation between image
quality and body weight, as shown for the present study
in Figure 2. Notghi et al used a linear fit instead of
power-law fit, despite a similar distribution.5 This
resulted in relatively large differences in the multipli-
cation factor for heavy patients, as illustrated in
Figure 6. Moreover, they derived their formula in
patients weighing less than 110 kg. Extrapolation of
this formula might therefore result in inaccurate correc-
tions for patients over 110 kg. The differences in
correction formulas might also be due to different
scanner specifications, such as collimator design, geo-
metrical detector configuration, and moving or
stationary detectors. This could explain the difference
in correction formula between the present study and the
study performed on a CZT-SPECT scanner using a
comparable methodology.9
The current study has some limitations. First, a
decreasing image quality for heavier patients was still
found in group B, possibly indicating the limited effect
of applying the new protocol. Nevertheless, the mea-
sured photon counts became independent of patients’
size after applying the new protocol. Moreover, the
significant relation between image quality and photon
counts suggests that a constant number of photon counts
result in a constant image quality, as previously
demonstrated using a CZT-based camera.9 The still
existing relation between image quality and weight in
group B might be due to readers being susceptible for
perfusion defects in MPI SPECT. Patient scans with
perfusion defects had a significantly lower image
Figure 5. Measured photon counts as a function of body weight for (A) group A (fixed dose) and
(B) group B (body weight depending protocol). The lines represent the linear fits where in (A) the
two fits correspond to patients weighing less and more than 100 kg. The slope of the fit did
significantly differ from zero in group A (P\ .001), whereas the measured photon counts became
independent of body weight after applying the new protocol (P = .29).
Figure 6. Differences in the proposed correction factors to
adjust the tracer dose or scan time for leaner and heavier
patients, normalized to an average patient of 80 kg. Included
studies are Taylor et al differentiating between males and
females,6 Verger et al,7 O’Connor et al,4 van Dijk et al (CZT-
SPECT),9 Notghi et al,5 and the present study (van Dijk et al,
conventional SPECT).
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quality, and these patients were also significantly heav-
ier in group B, possibly explaining the decreasing image
quality for heavier patients.16,17 Second, the proposed
formula corrects for the varying image quality but does
not represent the minimal tracer dose to administer to
obtain an accurate diagnostic image quality, as previ-
ously performed on a CZT-camera.18,19 The proposed
formula was based on the average photon counts
measured in group A. Hence, the mean radiation
exposure was comparable between group A and B,
whereas the radiation justification improved in group B,
as illustrated in Figure 3. Moreover, four (3%) images
were scored as poor in group A vs none in group B, and
only five (3%) and ten (8%), respectively, were scored
as excellent. This might indicate that increasing or
decreasing the tracer dose and scan time product would
not be necessary. It would lead to either an unacceptable
amount of poor images or many excellent images, which
is considered undesirable. Third, the tracer doses men-
tioned in this study are absolute activities including
possible residual activities in the syringes. An internal
study revealed that 10.6% ± 1.2% Tc-99m tetrofosmin
remained in the syringe after administration. The small
variation indicates the limited influence on our results.
Finally, the variation in photon counts between patients
with comparable body weights is still relatively large in
group B, as observed in previous studies.4-7,9 This might
be due to the large variation in Tc-99m tetrofosmin
uptake,16,17 influence of gastro-intestinal activity despite
the cardio-specific regions of interests, different body
compositions such as varying tissue layer between heart
and scanner or size of the myocardium, heart function,
liver excretion, and/or gender differences.6,9
Our present findings demonstrate the added value of
applying patient-specific dose and scan time protocols in
clinical practice for a conventional SPECT camera. This
protocol can be adopted using different settings and/or
type of SPECT camera by multiplying the currently
applied tracer dose and scan time product for an average
patient of 80 kg by the correction factor as shown in
Figure 6. This formula is based on patients with body
weights ranging between 60 and 130 kg. Therefore,
caution should be taken by extrapolating this formula to
patients outside this body weight range. The patient
population we encounter in clinical practice might not
be fully representative for other institutions encounter-
ing even heavier patients with higher BMIs. However,
we could not include a sufficient number of patients
heavier than 130 kg to be able to further extrapolate the
protocol for these patients. Moreover, when clinically
implementing this formula, it is advised to validate
whether the proposed correction formula holds true for
the applied settings and type of scanner used.
CONCLUSIONS
The use of a fixed tracer dose of Tc-99m tetrofos-
min in MPI using a conventional SPECT camera results
in a decreasing image quality in heavier patients.
Application of the derived patient-specific tracer dose
and scan time protocol, Aadmin (MBq) = 223body
weight (kg)0.65/Tscan (min), resulted in an image quality
less dependent on weight. This provides a better
radiation exposure justification. The results are most
likely independent of the type of SPECT camera used,
and, hence, adoption of patient-specific dose and scan
time protocols is recommended.
NEW KNOWLEDGE GAINED
A constant image quality can be obtained in MPI
using conventional SPECT by application of a body-
weight-dependent activity and scan time protocol. This
protocol corrects for the higher photon attenuation in
heavier patients. It results in a number of measured
photon counts which is independent of patients’ size.
This study shows good agreement with the study on a
CZT-camera, making these observations applicable to
all SPECT cameras.
Table 3. Derived body-weight depending Tc-
99m tetrofosmin tracer dose when using a fixed
scan time of 10 minutes in stress MPI using a
conventional SPECT camera
Body weight (kg)
Tracer dose
(MBq) (mCi)
\60 319 8.6
65 347 9.4
70 366 9.9
75 384 10.4
80 402 10.9
85 419 11.3
90 436 11.8
95 453 12.2
100 470 12.7
105 486 13.1
110 502 13.6
115 518 14.0
120 534 14.4
125 549 14.8
130 564 15.3
[130 564 15.3
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